Chimerix Inc(CMRX) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Current Price

$8.15

RSI

29.656

Beta:

1.637617

February 25, 2021
2.8M
-9M

-83.449 %
20.103 %
-230.456 %
81.289 %

$6,445,000
$3,449,000
$1,701,000
$4,494,000
$5,702,000
$10,762,000
86.866 %
102.763 %
-164.198 %
-26.880 %
-88.741 %

$-43,522,000
$-112,576,000
$-69,474,000
$-69,824,000
$-76,390,000
$-117,372,000
158.665 %
-38.287 %
0.504 %
9.404 %
53.648 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.